Advagene Biopharma Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	55.33	52.82	65.19	18.01	14.33
Short-Term Investments	79.5	149.5	60	85	209.5
Cash & Short-Term Investments	134.83	202.32	125.19	103.01	223.83
Cash Growth	-33.36%	61.61%	21.54%	-53.98%	-18.16%
Other Receivables	23.39	21.96	20.27	19.2	16.59
Receivables	23.39	21.96	20.27	19.2	16.59
Prepaid Expenses	0.79	0.54	0.95	3.61	3.57
Total Current Assets	159.01	224.82	146.41	125.82	244
Property, Plant & Equipment	7	6.89	1.04	3.22	5.41
Other Intangible Assets	-	-	-	9.81	9.02
Other Long-Term Assets	0.5	0.5	0.48	1.98	1.98
Total Assets	166.51	232.21	147.93	140.84	260.41
Accounts Payable	1.46	0.75	0.87	0.56	0.56
Accrued Expenses	8.06	4.7	5.99	6.05	5.79
Current Portion of Leases	1.32	1.26	-	1.35	1.27
Other Current Liabilities	0.78	0.4	1.11	0.46	0.65
Total Current Liabilities	11.61	7.11	7.97	8.42	8.27
Long-Term Leases	2.65	4.56	-	0.65	2.57
Total Liabilities	14.26	11.67	7.97	9.08	10.84
Common Stock	593.8	593.8	533.8	493.49	492.92
Additional Paid-In Capital	-	90	60.39	3.12	95.12
Retained Earnings	-441.55	-463.26	-454.22	-364.85	-338.47
Shareholders' Equity	152.25	220.54	139.96	131.76	249.57
Total Liabilities & Equity	166.51	232.21	147.93	140.84	260.41
Total Debt	3.97	5.82	-	2.01	3.84
Net Cash (Debt)	130.87	196.5	125.19	101	220
Net Cash Growth	-33.40%	56.96%	23.95%	-54.09%	-17.87%
Net Cash Per Share	2.20	3.60	2.48	2.05	4.51
Filing Date Shares Outstanding	59.38	59.38	53.38	49.35	49.29
Total Common Shares Outstanding	59.38	59.38	53.38	49.35	49.29
Working Capital	147.4	217.72	138.44	117.39	235.72
Book Value Per Share	2.56	3.71	2.62	2.67	5.06
Tangible Book Value	152.25	220.54	139.96	121.95	240.55
Tangible Book Value Per Share	2.56	3.71	2.62	2.47	4.88
Machinery	2.99	1.21	1.36	1.4	3.09